ŌURA secures $75M to enhance health data integration and global expansion

Finnish smart ring manufacturer company ŌURA has raised $75 million in a Series D financing round from medical device maker Dexcom, reaching the value of $5 billion. Combining Dexcom glucose data with the biometrics collected by ŌURA Ring, the deal will provide users of both products with a more complete picture of their overall health. The company shared the news via a press release.

About ŌURA Ring

ŌURA was founded in 2013, and has offices in Oulu, Helsinki, San Francisco, and San Diego. ŌURA’s main product, ŌURA Ring, a smart ring for personalized health data, offers insights and daily guidance, promoting healthy habits and connecting individual well-being with collective outcomes.
The ŌURA Ring's sensors collect data on more than 20 biometrics like heart rate, heart rate variability, blood oxygen levels, body temperature, menstrual cycles, and movement to track metrics like sleep patterns and activity levels.
According to the company, the product now has more than 1 million members.

Image: ŌURA Ring

“Partnering with ŌURA gives us the opportunity to redefine the category again, integrating data from Dexcom glucose biosensors with the continuous insights and metrics measured by ŌURA Ring. This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition, and their glucose,” said Matt Dolan, executive vice president of strategy and corporate development at Dexcom.

Investment details

The $75 million Series D investment round was led by the San Diego-based medical device maker company Dexcom.

Dexcom was founded in 1999 and develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management.
Following the deal, both companies will launch integrations enabling data to flow between Dexcom products, including glucose biosensors and apps, and the ŌURA Ring and its app. The first integration resulting is expected to launch in H1 of 2025.
As part of this integration, consumers who use both Dexcom glucose biosensors, including its over-the-counter product Stelo, and the ŌURA Ring can track their glucose levels and understand the impact of behaviors and biology on their metabolic health.

ŌURA plans to use fresh funding from Dexcom to further expand on its mission of leaving a footprint on international markets and fueling its M&A deals.